Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Expands Inflammation Pipeline With Avidia Purchase

This article was originally published in The Pink Sheet Daily

Executive Summary

$380 mil. deal for private company gives Amgen Phase I interleukin 6 inhibitor, novel protein development platform.

You may also be interested in...



Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care

Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.

AstraZeneca Commits $100 Million To MedImmune Ventures

The UK-based pharma’s corporate venture arm now has $400 million under management in an evergreen fund, with an expanded global focus that includes health care information technology.

Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”

Related Content

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel